


## Modified MMAF

<b>Cat. No.:</b>	HY-141594
<b>CAS No.:</b>	1352202-47-1
<b>Molecular Formula:</b>	C <sub>45</sub> H <sub>73</sub> N <sub>7</sub> O <sub>8</sub>
<b>Molecular Weight:</b>	840.1
<b>Target:</b>	Microtubule/Tubulin
<b>Pathway:</b>	Cell Cycle/DNA Damage; Cytoskeleton
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

<b>Description</b>	Modified MMAF, an ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC). Modified MMAF can be used for the targeted research of cancer <sup>[1]</sup> .
<b>In Vitro</b>	MMAF inhibits anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O and Caki-1 cells with IC <sub>50</sub> s of 119, 105, 257 and 200 nM in vitro cytotoxicity assay <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection [published correction appears in Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added]]. Cancer Res. 2009;69(6):2358-2364.

[2]. Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17(1):114-124.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA